在最新研究中，德康医疗的G7连续血糖监测系统展现出了显著优势。对于正在使用GLP-1受体激动剂类药物的参与者而言，配合使用德康G7设备，其糖化血红蛋白水平平均降低了1.4%。这一降幅远超对照组仅0.2%的改善，凸显了联合监测方案在血糖管理中的增效作用。研究数据进一步证实，将先进的实时血糖监测技术与新型降糖药物相结合，能为患者带来更为精准和有效的糖尿病控制效果。
在最新研究中，德康医疗的G7连续血糖监测系统展现出了显著优势。对于正在使用GLP-1受体激动剂类药物的参与者而言，配合使用德康G7设备，其糖化血红蛋白水平平均降低了1.4%。这一降幅远超对照组仅0.2%的改善，凸显了联合监测方案在血糖管理中的增效作用。研究数据进一步证实，将先进的实时血糖监测技术与新型降糖药物相结合，能为患者带来更为精准和有效的糖尿病控制效果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.